From: Mesenchymal stem cells in preclinical cancer cytotherapy: a systematic review
MSC suitability for cytotherapy | ||||||
---|---|---|---|---|---|---|
Most favorable attributes Best option ✓ | Some favorable attributes Alternative use (✓) | Detrimental effects questionable/contraindicated ? | ||||
(+ 1) | (+ 0.5) | (− 0.5) | ||||
Cytotherapy evaluation areas [links to supportive evidence in the review] | Adequacy | 1 | MSC donor tissue abundance/availability Ease of isolation/derivation Harvest yield [4.1.3, 4.1.4] | UC AT | BM | |
2 | Ease of sub-culture manipulation Expansion/upscaling potential [4.1.4] | UC | AT GM-BM | |||
Safety | 3 | Genomic stability [4.2] | UC | AT | BM GM-MSC | |
4 | Host integration/immunogenicity [4.2, 4.3.1, Table 4] | UC | GM-AT | |||
Efficacy | 5 | Robust target-specific anti-cancer action [Table 5, Additional file 6: Figure S6] | UC (vs. breast) GM-BM (vs. lung) GM-BM (vs. neural) | GM-UC (vs. breast) GM-UC (vs. lung) GM-AT (vs. neural) | BM (vs. breast) | |
6 | % frequency anti- vs. pro-tumorigenic events [Table 1, Figs. 3, 4, 5b, and 6] | UC (breast, lung) GM-MSC | AT (neural) | BM (breast, colorectal | ||
MSC total scores | UC:  6 * (+1) = + 6 GM-BM:  2 * (+1) = + 2 AT:  1 * (+1) = + 1 GM-MSC:  1 * (+1) = + 1 | AT:  3 * (+0.5) = + 1.5 BM:  1 * (+0.5) = + 0.5 GM-AT:  2 * (+0.5) = + 1 GM-UC:  2 * (+0.5) = + 1 | BM:  3 * (-0.5) = - 1.5 GM-MSC  1 * (-0.5) = - 0.5 | |||
Ranking: | ||||||
Tissue-specific | Cord (+ 7) > fat (+ 3.5) > marrow (+ 1) | |||||
Fetal vs. adult | Fetal (+ 7) > adult (+ 4.5) | |||||
Naïve vs. GM | Naïve (+ 7.5) > GM (+ 4.5) |